GRC 54276

GRC 54276 is an orally administered, small molecule inhibitor of hematopoietic progenitor kinase 1 (HPK1), developed for the treatment of advanced solid tumors and lymphomas. HPK1 acts as a negative regulator of T-cell and B-cell receptor signaling, making it a promising target in immuno-oncology. By inhibiting HPK1, GRC 54276 aims to enhance anti-tumor immune responses both as monotherapy and in combination with immune checkpoint inhibitors such as pembrolizumab or atezolizumab. Preclinical studies have shown that the drug can potentiate cytokine release from dendritic cells and T-cells, reverse adenosine- and PGE2-mediated immunosuppression, increase cytotoxic T cell infiltration in tumors, and improve efficacy when combined with other immunotherapies. The drug is currently being evaluated in phase 1/2 clinical trials for patients with advanced solid tumors and lymphomas[1][2][3][4][5][6][7].